Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612133 | 1.00 | PTGS2 (0.55) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL8785740 | 0.88 | PTGS2 (0.50) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL1058736 | 0.87 | MAPK1 (0.50) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL27424167 | 0.86 | TSHR (0.55) | PTGS2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL28206194 | 0.85 | CYP1A2 (0.48) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL1421009 | 0.85 | PTGS2 (0.47) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL8090536 | 0.85 | PTGS2 (0.47) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL16532812 | 0.84 | PTGS2 (0.46) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL34470376 | 0.84 | MAPT (0.47) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL30418806 | 0.84 | NNMT (0.50) | PTGS2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026088205-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | INTONATION RESEARCH LABORATORIES PRIVATE LIMITED. (IN) | 2026-04-30 | — | — | WO | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| CN-110498784-B | Nobiletin derivatives or pharmaceutically acceptable salts thereof, and preparation method and application thereof | 广东克冠达医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3856179-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-107848971-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-03-26 | — | — | CN | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| CN-110498784-A | A kind of Nobiletin derivative or its pharmaceutically acceptable salt and its preparation method and application | ZHIYUAN MEDICINE TECH QINGYUAN CO LTD | 2019-11-26 | — | — | CN | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-1227847-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001024827-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | PTGS2 2757/4885CA12 4431/4885CA1 4777/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | PTGS2 2757/4885CA12 4431/4885CA1 4777/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGS2 984/4885CA12 4334/4885CA1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.